BLS Pharmaceuticals Limited (ASX:BLS)

BLS Pharmaceuticals Revenue

In the fiscal year ending June 30, 2026, BLS Pharmaceuticals had annual revenue of 73.91M AUD with 152.42% growth. BLS Pharmaceuticals had revenue of 42.76M in the half year ending June 30, 2026, with 797.99% growth. That makes BLS Pharmaceuticals the 27,716th largest company in the world by revenue and 477th in Australia.

• Revenue: 73.91M
• Revenue Growth: +152.42%
• P/S Ratio: 3.07
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 226.85M

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Manufacture/sales - Australia 71.14M 95.9%
• Plant Based - UK/EU/JPN/AUS 2.47M 3.3%
• Wholesale - PCC/USA 554.87K 0.7%

By Geography

Chart

• Australia 71.69M 96.7%
• Europe 1.19M 1.6%
• United Kingdom 1.08M 1.5%
• Japan 199.53K 0.3%

Fiscal year ended Jun 30, 2026 See the full BLS Pharmaceuticals breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	73.91M	44.63M	152.42%
Jun 30, 2025	29.28M	19.64M	203.66%
Jun 30, 2024	9.64M	4.34M	81.98%
Jun 30, 2023	5.30M	4.84M	1,042.88%
Jun 30, 2022	463.64K	-1.74M	-78.97%

Data Source: S&P Global Market Intelligence Last updated: Aug 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 31, 2026

Data Sources Report a data error